Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de Robert Kramer
Age : 62
Public asset : 10,285,383 USD
Country of residence : Unknown
Linked companies : Emergent BioSolutions Inc.

Biography of Robert Kramer 
Robert G. Kramer occupies the position of President, Chief Executive Officer & Director at Emergent BioSolutions, Inc. In the past he occupied the position of President of Emergent BioDefense Operations Lansing, Inc. Mr. Kramer received an MBA from the University of Western Kentucky and an undergraduate degree from Clemson University.


Current positions of Robert Kramer 
Holdings of Robert Kramer 
Robert Kramer : Personal Network 
Most Read News 
09/22WILLIAM ACKMAN : Ackman's Pershing Square fund surges as Universal soars in stock debut
RE
09/14BRAD SMITH : Microsoft to buy back up to $60 billion in shares; names Brad Smith vice chair
RE
09/13MARTIN SORRELL : Sorrell's S4 Capital raises annual profit outlook for a third time
RE
09/24CATHIE WOOD : Chinese crackdown on bitcoin another blow to Cathie Wood's ARK ETF
RE
09/14CATHIE WOOD : ARK Invest's Wood expects market rotation back to growth stocks
RE
09/22CATHIE WOOD : ARK's Cathie Wood says Wall Street not in a bubble
RE
09/24ELON MUSK : New semiconductor plants will end global auto chip shortage next year -Tesla's Musk
RE
09/21JEFF BEZOS : UK's Johnson discussed taxation with Amazon's Bezos
RE
09/17STELIOS HAJI-IOANNOU : EasyJet shareholder Stelios Haji-Ioannou shuns rights issue -source
RE
09/24BARRY DILLER : Stock Futures Weaken After Evergrande Payment Deadline Passes
DJ
More news


© 2021 People and Ownership :   
Robert Kramer : Connections 


Latest news about Robert Kramer 
07/29ASTRAZENECA : Emergent to resume J&J COVID-19 vaccine production at Baltimore plant
RE
07/29ASTRAZENECA : REFILE-UPDATE 3-Emergent to resume J&J COVID-19 vaccine production at Baltimore plant
RE
07/29EMEA MORNING BRIEFING : Stocks to Open Lower After -2-
DJ
06/11ASTRAZENECA : U.S. FDA asks J&J to discard millions of COVID-19 vaccine doses
RE
05/27FDA, J&J Near Deal for Covid-19 Vaccine Production at Baltimore Plant -- Update
DJ
05/19Covid-19 Vaccine Maker Blames Problems on Producing Two Different Shots -- 2nd Update
DJ
05/19ASTRAZENECA : Emergent plans to fix issues that halted vaccine production early as July -U.S. House memo
RE
More news